Oral drug to calm hippocampus overactivity and improve memory in early Alzheimer’s
Official title: Preclinical and early clinical development of a GABA-A a5 PAM
Funded at Agenebio, INC. · NIH-11180122 · Data updated 2026-11-12
An oral medication is being developed to reduce overactive brain circuits in the hippocampus and help adults with mild cognitive impairment from Alzheimer’s disease remember better.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Agenebio, INC. NIH-funded |
| Lab location | 1 site (Baltimore, UNITED STATES) |
| Project start | September 1, 2022 |
| Project end | August 31, 2026 |
| Funding year | 2025 |
| Award (this year) | $1,078,000 |
| NIH project number | 5U01AG074950-04 |
| Project ID | NIH-11180122 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults diagnosed with Mild Cognitive Impairment due to Alzheimer’s disease (amnestic MCI) would be the most likely candidates for early participation.
✕Less likely to help
People with more advanced Alzheimer’s dementia, non‑Alzheimer’s causes of memory loss, or medical conditions that rule out trial participation are unlikely to benefit from this program.
What this research studies
You would be hearing about BPN-27473, a pill designed to boost a specific GABA-A α5 receptor to increase inhibitory control in the hippocampus. Researchers are using lab and animal work plus early human testing to find safe doses and signs that the drug lowers hippocampal overactivity linked to memory problems. Early clinical work will likely include small patient studies with memory tests and brain measures such as imaging or other biomarkers. The goal is to show safety and initial signals of memory benefit before moving to larger trials.
Why it matters
Potential benefit: If successful, this approach could slow memory decline and improve memory function in people with MCI due to Alzheimer’s disease.
How similar studies have gone: Related work lowering hippocampal overactivity with low‑dose levetiracetam showed promising memory benefits in animal models and early human MCI studies, but an α5‑selective drug like this is a newer and less tested approach.
Where this research is happening
-
Agenebio, INC.
Baltimore, United States Active
Researchers
- Principal investigator: Payie, Kenneth G — Agenebio, INC.
- Study coordinator: Payie, Kenneth G
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.